Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

EN
History
Home  >  About Us  >  History
Course of Development

Since its establishment in 1995, Hansoh Pharma has been working to address unmet clinical needs, accelerating the pace of technological innovation, and making unremitting efforts to improve human health and quality of life.

  • 2024
    The company obtained an exclusive license from Qyuns to develop and commercialize QX004N within China (including Hong Kong, Macau and Taiwan) Hansoh Pharma Launches Building Project for Global R&D HQ in Shanghai The company obtained exclusive licensing from Biotheus for the global development, production, and commercialization of HS-20117 (introduced as project name PM1080) for use in bispecific antibody conjugate products, with approval to further sublicense
  • 2023
    The proportion of innovative drugs and collaborative products revenue increased to 67.9% Saint Luolai (Pegmolesatide Injection), was included in the National Reimbursable Drug List Hansoh Pharma's MSCI ESG rating was upgraded to AA, achieving a leading position among global industry peers. GSK enters exclusive license agreement with Hansoh for HS-20089、HS-20093 The invention patent "EGFR Inhibitor and Preparation and Application Thereof" for Ameile won the 24th China Patent Gold Award Saint Luolai, Hansoh’s seventh innovative drug and the global unique once-monthly peptide-based highly specific EPO receptor activator, granted approval for marketing Hansoh Pharma Included in the First “S&P Sustainability Yearbook (China)”, S&P Global ESG Score Makes It into Top 1% Ameile(Aumolertinib Mesylate Tablets)was included in the National Reimbursable Drug List XINYUE (Inelizumab Injections), was included in the National Reimbursable Drug List
  • 2022
    The proportion of innovative drugs revenue increased to 53.4% Reported six BD collaborations, including five license-in deals of blockbuster innovative products, and one in-depth technology cooperation Changzhou Hansoh Pharmaceutical Co. , Ltd. received its first ISO 50001 certification for energy management systems, completing the full certification coverage (energy and environmental management systems) for Hansoh’s facilities S&P CSA score rose to 63, up more than 57% on a sequential basis XINYUE (Inelizumab Injections), Hansoh’s sixth innovative drug and the world's only anti-CD19 mAb for the treatment of NMOSD, was approved for marketing The Journal of Clinical Oncology (JCO), an internationally renowned oncology journal, published a paper on the AENEAS study of Ameile(Aumolertinib Mesylate Tablets), which was the first publication of the clinical data of an original Chinese third-generation EGFR-TKI in the official ASCO journal 21 full-text papers on Ameile were published in SCI journals, with a cumulative impact factor of 153.1 points 34 Ameile studies gained spotlight at WCLC, ESMO, ESMO ASIA, ASCO and other international academic events of oncology The 96-week data from the large-scale Phase III clinical study of Hengmu (Tenofovir Amibufenamide Tablets) was published in the Journal of Clinical and Translational Hepatology (JCTH), an internationally renowned academic journal of hepatology
  • 2021
    Hansoh Pharma's headquarters building was inaugurated in Shanghai Announced the opening of the Biomedicine R&D Center, vigorously promoting the momentum of innovative biologics development Ranked 1,616th in Forbes Global 2000 MSCI upgraded Hansoh Pharma's ESG rating to A Ameile(Aumolertinib Mesylate Tablets) received approval for first-line indication Hengmu, China's first original oral anti-HBV drug, came into the market Hengmu(Tenofovir Amibufenamide Tablets)was included in the National Reimbursable Drug List
  • 2020
    Recognized as Green Supply Chain Management Enterprise by MIIT,China's Best Industrial Enterprises in Pharmaceutical R&D Pipeline and China Pharmaceutical Enterprise CSR Leading Enterprise Award Ranked 37th among pharmaceutical companies worldwide Phase I of Changzhou Hansoh Pharmaceutical Co. , Ltd. was put into operation and Phase II was started The "National Category 1 Long-acting GLP-1 Hypoglycemic Drug Polyethylene Glycol Loxenatide and Its Formualtions R&D and Industrialization Project" was awarded the Commendation Award of China’s Grand Industrial Awards by China’s Federation of Industrial Economics Ameile(Aumolertinib Mesylate Tablets), China's first original third-generation EGFR-TKI innovative drug, hit the market Three innovative drugs,Ameile(Aumolertinib Mesylate Tablets), Hansoh Xinfu(Flumatinib Mesylate Tablets) and Fulaimei(PEG-Loxenatide for Injection) entered the National Reimbursable Drug List Morinidazole invention patent and Tigecycline invention patent were awarded China Patent Excellence Award and China Patent Silver Award by China National Intellectual Property Administration respectively
  • 2019
    Hansoh Pharma (03692.HK) was listed in Hong Kong Stock Market, embarking on a new journey of development China Pharmaceutical Enterprise CSR Leading Enterprise Award Green Enterprise Management Award China's Best Industrial Enterprises in Pharmaceutical R&D Pipeline (2rd place) Hansoh Xinfu( Flumatinib Mesylate Tablets), China's first independently developed second-generation Class 1 innovative drug for CML, came into the market Fulaimei(PEG-Loxenatide for Injection), the world's first PEGylated long-acting hypoglycemic drug and China's first long-acting GLP-1 hypoglycemic drug, hit the market
  • 2018
    China's Best Industrial Enterprises in Pharmaceutical R&D Pipeline (2rd place) Jiangsu Hansoh Pharmaceutical Group Co., Ltd. was established, complementing the strategic layout of biopharmaceutical industrial base Oulanning (Olanzapine Tablets) was the first to pass the consistency evaluation Xinwei (Imatinib Mesylate Tablets) was the first to pass the consistency evaluation Fulaidi (Repaglinide Tablets) was the first to pass the consistency evaluation Hengsen (Micafungin Sodium for Injection) came into the market
  • 2017
    National Intellectual Property Exemplary Enterprise Ranked 19th in the Top 100 Ranking of China's Pharmaceutical Industry Ranked 23rd in Top 100 Pharmaceutical Companies in China 2016 Recognized as a Contract-abiding and Trustworthy Company at the provincial level for six consecutive years Xinwei (Imatinib Mesylate Tablets) was named to the "China Pharmaceuticals • Top Brands" list Mailingda(Morinidazole Sodium Chlorride for Injection) entered the National Reimbursable Drug List
  • 2016
    Recognized as an Intellectual Property Exemplary Enterprise by China National Intellectual Property Administration [Oulanning] (Olanzapine Tablets) received China Patent Excellence Award from China National Intellectual Property Administration [Xinwei] (Imatinib Mesylate Tablets) received the first prize for the Advancement of Science and Technology from the National Federation of Industry & Commerce Pulaile (Pemetrexed Disodium for Injection), was approved by the PMDA,Japan
  • 2015
    The patent of "New Synthetic Process of Important Intermediate of New Oncology Drug Gemcitabine" won China Patent Gold Award
  • 2014
    The first Class 1.1 innovative drug, Mailingda, came into the market, which was the world's first innovative nitroimidazole anti-anaerobic drug in 40 years "Development and Application of New Antipsychotic Drug Olanzapine and Its Formulations" won the second prize of the National Science and Technology Progress Award
  • 2013
    All production lines in Hansoh obtained GMP certificate "Development and Industrialization of Gemcitabine Hydrochloride for Injection, a New Oncology Drug" won the second prize of the National Science and Technology Progress Award Zefei (Gemcitabine Hydrochloride for Injection) was approved by the FDA
  • 2012
    Recognized as a National Technology Innovation Exemplary Enterprise The Administrative R&D Center at Lianyungang Headquarters was put into use Gainuo (Vinorelbine Tartrate Injection)and Zefei(Gemcitabine Hydrochloride for Injection) passed the FDA certification, embarking on a new international journey
  • 2011
    Shanghai R&D Center, i.e. Shanghai Hansoh BioMedical Co., Ltd., was established
  • 2009
    Managed as a group and changed into Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • 2006
    Approved to establish a postdoctoral research station
  • 2003
    Passed the FDA certification with "zero defect", starting the new international journey The API vinpocetine tartrate passed the FDA certification with "zero defect"
  • 2002
    Recognized as a Key National High-tech Enterprise Started the research and development of Class 1.1 innovative drugs, becoming one of the first companies in China to tap the potential of innovative drugs
  • 2001
    Zefei( Gemcitabine Hydrochloride for Injection) and Oulanning (Olanzapine Tablets) came into the market successively, establishing a leading role in the development and production of oncology and psychotropic drugs in China
  • 2000
    Launched first GMP production workshop in Lianyungang, Jiangsu Province and commenced production of solid oral formulations.
  • 1999
    Gainuo ( Vinorelbine Tartrate Injection) came into the market, becoming an important milestone in the domestic oncology field
  • 1997
    Meifeng(Tabellae Cefalexini Lente Liberantes) hit the market, marking the exclusive launch of new dosage form in China and becoming the first blockbuster product
  • 1995
    Establishment of Lianyungang Haosen Pharmaceutical